Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib in PIK3CA-mutated lymphatic malformations
2023-504146-60-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in lymphangioma comparing Alpelisib with Placebo (2 arms). Primary endpoint: Week 24 radiologic response in Stage 2 confirmatory phase. Planned start Feb 2024; status: authorised.
02
Drugs
alpelisib
03
Conditions
lymphangioma
Beyond the preview
Go deeper on 2023-504146-60-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504146-60-00.